Molecular mechanisms of insulin resistance that impact cardiovascular biology

Diabetes

Volumn 53, Issue 11, 2004, Pages 2735-2740

  Wang, Cecilia C Low ^a   Goalstone, Marc L ^a   Draznin, Boris ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENZYME PHOSPHORYLATION; GLUCOSE HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; LIFESTYLE; PATHOPHYSIOLOGY; PRENYLATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR PHYSIOLOGY; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE;

EID: 7044263120     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.11.2735     Document Type: Review

References (55)

1. Reaven GM: Insulin resistance and its consequences. In Diabetes Mellitus: A Fundamental and Clinical Text. 3rd ed. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott, Williams & Wilkins, 2004, p. 899-915
2. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M: Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest 101:86-96, 1998
3. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1998
4. Ginsberg H: Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458, 2000
5. Flakoll PJ, Jensen MD, Cherrington AD: Physiologic action of insulin. In Diabetes Mellitus: A Fundamental and Clinical Text. 3rd ed. LeRoith D, Taylor SI, Olefsky JM, Eds. Lippincott, Williams & Wilkins, 2004, p. 165-181
6. Blankard WG, Clore JN: Insulin effects on substrate metabolism. In Clinical Research in Diabetes and Obesity. Draznin B, Rizza R, Eds. Totowa, New Jersey, Humana Press, 1997, p. 205-220
7. Cheatham G, Kahn CR: Insulin action and the insulin signaling network. Endocrin Rev 16:117-142, 1995
8. White MG: The IRS-signaling network. Mol Cell Biochem 182:3-11, 1998
9. Shepherd PR, Kahn BB: Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-257, 1999
10. Shulman GI: Cellular mechanisms of insulin resistance in humans. Am J Cardiol 84:3J-10J, 1999
11. Sasaoka T, Rose DW, Jhun BH, Saltiel AR, Draznin B, Olefsky JM: Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 269:13689-13694, 1994
12. Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM, Kobayashi M: Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. Endocrinol 137:4427-4434, 1996
13. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL: Characterization of selective resistance to insulin signaling in the vasculature of obese Zuker (fa/fa) rats. J Clin Invest 104:447-457, 1999
14. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320, 2000
15. Zecchin HG, Bezerra RMN, Carvalheira JBC, Carvalho-Filho MA, Metze K, Franchini KG, Saad MJA: Insulin signaling pathways in aorta and muscle from two animal models of insulin resistance, the obese middle aged and the spontaneously hypertensive rats. Diabetologia 46:479-491, 2003
16. Law RE, Meehan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905, 1996
17. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B: Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 277:1794-1799, 2002
18. Wang CCL, Gurevich I, Draznin B: Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52:2562-2569, 2003
19. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94:2511-2515, 1994
20. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172-1179, 1994
21. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Hergert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo. Circulation 101:676-681, 2000
22. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101:1539-1545, 2000
23. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348, 2001
24. 1179. J Biol Chem 276:30392-30398, 2001
25. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY: Vascular endothelial growth factor expression of intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectine through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276:7614-7620, 2001
26. Madonna R, Pandolfi A, Massaro M, Consoli A, DeCaterina R: Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 47:532-536, 2004
27. Owens GK: Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75:487-517, 1995
28. Hayashi K, Saga H, Chimori, Kimura K, Yamanaka Y, Sobue K: Differentiated phenotype of smooth muscle cells depends on signaling pathways through insulin-like growth factors and phosphatidylinositol 3-kinase. J Biol Chem 273:28860-28867, 1998
29. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R: Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 93:1266-1274, 1994
30. Goalstone ML, Draznin B: Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes. J Biol Chem 271:27585-27589, 1996
31. Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 241-269, 1996
32. Seabra MC, Reiss Y, Casey PJ, Brown MS, Goldstein JL: Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell 65:429-434, 1991
33. Goalstone M, Carel K, Leitner JW, Draznin B: Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen- activated protein kinase pathway. Endocrinology 138:5119-5124, 1997
34. Goalstone ML, Leitner JW, Berhanu P, Sharma PM, Olefsky JM, Draznin B: Insulin signals to prenyltransferases via the Shc branch of intracellular signaling. J Biol Chem 276:12805-12812, 2001
35. Leitner JW, Kline T, Carel K, Goalstone ML, Draznin B: Hyperinsulinemia potentiates activation of p21Ras by growth factors. Endocrinology 138: 2211-2214, 1997
36. Chappell J, Golovhenko I, Wall K, Stjernholm R, Leitner JW, Goalstone M, Draznin B: Potentiation of Rho-A-mediated lysophosphatidic acid activity by hyperinsulinemia. J Biol Chem 275:31792-31797, 2000
37. Goalstone ML, Wall K, Leitner JW, Kurowski T, Ruderman N, Pan SJ, Ivy JL, Moller DE, Draznin B: Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals. Diabetologia 42:310-316, 1999
38. Draznin B, Miles P, Kruszynska Y, Olefsky J, Friedman J, Golovchenko I, Stjernholm R, Wall K, Reitman M, Accili D, Cooksey R, McClain D, Goalstone M: Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia. Endocrinol 141:1310-1316, 2000
39. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B: Hyperinsulinemia enhances transcriptional activity of nuclear factor-kB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 87:746-752, 2000
40. Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Carel K, Scott S, Nadler J, Sowers JR, Draznin B: Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinol 139:4067-4072, 1998.
41. Dandona P, Aljada A, Mohanty P: The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45:924-930, 2002.
42. Grandy SM, Garber A, Goldberg R, Havas S, Holman R, Launendola C, Howard WJ, Savage P, Sowers J, Vega GL: Prevention conference VI: diabetes and cardiovascular disease: writing group IV: lifestyle and medical management of risk factors. Circulation 105:153e-158e, 2002
43. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:837-853, 1998
44. Lehman JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
45. Mudaliar S, Henry RR: New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-2572, 2001
46. Ginsberg H, Plutzky J Sobel BE: A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 6:337-346, 1999
47. Hsueh WA, Jackson S, Law RE: Control of vascular cell proliferation and migration by peroxisome proliferator-activated receptor γ. Diabetes Care 24:392-397, 2001
48. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-isk patients: the heart prevention evaluation study investigators. N Engl J Med 342:145-153, 2000
49. Kintscher U, Lyon CJ, Law RE: Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 9:359-369, 2004
50. Sowers JR, Frohlich ED: Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 88:63-82, 2004
51. Folli F, Kahn CR, Hansen H, Bouchie J, Feener EP: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest 100:2158-2169, 1997
52. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Mieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:995-1003, 2002
53. Brenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
54. Lewis EJ, Hunsicker JG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
55. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S: Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 20:1879-1886, 2002